Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

Cellular activity of BM-ca, a novel humanized anti-CD20 antibody, was quantitatively compared with that of two other anti-CD20 antibodies used for clinical practice, rituximab and ofatumumab. The results of a complement-dependent cytotoxicity (CDC) assay revealed that the strongest antibody was ofat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Hideaki, Matsunaga, Yuka, Uchiyama, Yumiko, Nagura, Kenji, Komatsu, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639652/
https://www.ncbi.nlm.nih.gov/pubmed/23634281
http://dx.doi.org/10.1002/cam4.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639652/
https://www.ncbi.nlm.nih.gov/pubmed/23634281
http://dx.doi.org/10.1002/cam4.60

Ejemplares similares